| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Methodology and Biostatistics Unit, Centre Oscar Lambret and SIRIC ONCO LILLE, Lille. Department of Medical Oncology, University of Lyon I, Centre Leon Berard, Lyon, France. Department of Biostatistics, EORTC Headquarters, Brussels. Department of Urology, University Hospitals Leuven, Leuven, Belgium. Department of Urology, Radboud University Medical Centre, Nijmegan, The Netherlands. Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. Department of Urology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, The Netherlands. Methodology and Quality of Life in Oncology Unit, University Hospital of Besancon, Besancon. Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France. Department of Oncology, Ospedale San Donato, Arezzo, Italy. Department of Immunology, Cleveland Clinic Taussig Cancer Center, Cleveland, USA. Academic Urology Unit, University of Sheffield, Sheffield, UK. Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, USA. Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton. Department of Oncology, Cambridge University Health Partners, Cambridge, UK. Department of Medical Oncology, University Hospital of Nimes, Nimes, France. Division of Surgery, Mater Misericordiae Hospital and University College Dublin, Dublin, Ireland. Department of Urology, University Lille2 Nord de France, Lille, France. Department of Urology, Friedrich-Alexander University Erlangen-Nueremberg, Erlangen, Germany. Department of Medical Oncology, Institut Paoli-Calmettes, Marseille. Department of Medical Oncology, CHU Caremeau, Nimes. Department of Urology, CHRU, Strasbourg, France. MRC Clinical Trials Unit, University College London, London, UK. Department of Urology, CHU, Toulouse, France. Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic. Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France. Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK. Department of Academic Radiation Oncology, Centre Oscar Lambret and SIRIC ONCO LILLE, Lille, France. Department of Medical Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Department of Medical Oncology, Hopital Saint-Louis, APHP, Paris, France. Division of Oncology, USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, USA. Department of Medical Oncology, Hopital Saint Andre, Bordeaux. Department of Medical Oncology, Institut de cancerologie de l'Ouest-Rene Gauducheau, Nantes, France. Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Department of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium. Department of Medical Oncology, Institut Regional du Cancer Val d'Aurelle, Montpellier. Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. Division of Urology, University of Eastern Piedmont, Maggiore della Carita Hospital, Novara, Italy. Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. alt-title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO accession-num: 26371288 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN projectdagger |
Institut de Recherche en Cancérologie de
